Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23211002 | 0.98 | FFAR3 (0.33) | FFAR3KDM4EKMT2AOPRM1CYP4F2 | |
| SCHEMBL17040615 | 0.89 | — | — | |
| SCHEMBL15055670 | 0.83 | KDM4E (0.35) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL4189013 | 0.82 | KDM4E (0.32) | KDM4EKMT2A | |
| SCHEMBL5722406 | 0.81 | FFAR3 (0.39) | FFAR3CYP4F2CYP4A11 | |
| SCHEMBL28487708 | 0.80 | KDM4E (0.33) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL21564990 | 0.79 | FFAR3 (0.37) | FFAR3KMT2ACYP4F2CYP4A11 | |
| SCHEMBL28675361 | 0.79 | DGAT1 (0.31) | KMT2A | |
| SCHEMBL2146137 | 0.78 | OPRM1 (0.34) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 | |
| SCHEMBL4372857 | 0.78 | KDM4E (0.32) | KDM4EKMT2AOPRM1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566675-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250171443-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| CN-119613400-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247026-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4212529-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-112135824-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-11124511-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3774791-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112135824-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-08-13 | — | — | US | disclosed |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| WO-2019191707-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2024334-A2 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136607-A2 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300524-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
| US-10669271-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
| US-20200255424-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
| US-11124511-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
| US-12247026-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | FFAR3 59/4885KDM4E 2066/4885KMT2A 2455/4885 |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | FFAR3 4544/4885KDM4E 1185/4885KMT2A 733/4885 |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | FFAR3 4544/4885KDM4E 1185/4885KMT2A 733/4885 |
| US-20250171443-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3744/4885KDM4E 3674/4885KMT2A 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.